In this commentary, an expert faculty member discusses best practices for identifying and treating advanced cutaneous squamous cell carcinoma (cSCC), including strategies for integrating immune checkpoint inhibitors into treatment plans and management of immune-related adverse events.
Oncology NPs, PAs, and RNs
This program is supported by educational grants from Merck Sharp & Dohme Corp; Regeneron Pharmaceuticals, Inc. and Sanofi; and Taiho Oncology, Inc.
Nikhil I. Khushalani, MD: consultant/advisor: Array BioPharma, AstraZeneca, Bristol-Myers Squibb, Castle Biosciences, Genzyme, Immunocore, Incyte, Instil Bio, Iovance Biotherapeutics, Jounce Therapeutics, Merck, Nektar, Novartis, Pfizer, Regeneron; research support (paid to institution): Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Huya Bioscience International, Merck, Novartis, Regeneron, Replimune; individual publicly traded stocks and stock options: Amarin, Asensus Surgical, Bellicum Pharmaceuticals; other: Bristol-Myers Squibb, Celgene, Nektar, Regeneron, Replimune.
None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 105722O-CT1